LDS/Medical Tests/Kappa and Lambda Free Light Chains, Quantitative, Urine

Kappa and Lambda Free Light Chains, Quantitative, Urine

In normal patients immunoglobulins are produced by cells called plasma cells, as part of the immune response. Immunoglobulins are proteins used in defense against infectious organisms. Immunoglobulins are comprised of heavy chains (categorized by α, δ, ε, γ, or μ) and light chains (categorized by kappa (κ) and lambda (λ). Each immunoglobulin is made up of two identical heavy chain and two identical light chain components. The heavy chain is used to define the immunoglobulin’s class (IgG, IgA, IgM, IgD, IgE).

Testing for these immunoglobulin light chains and their ratios are used to diagnose and monitor patients with monoclonal gammopathies such as Multiple Myeloma, Waldenström macroglobulinemia, and Light-Chain Amyloidosis.

Serum free light chain tests are required by the International Myeloma Working Group and NCCN in the diagnostic workup for Multiple Myeloma.

Normally an immunoglobulin circulates in the blood stream with the heavy chains and light chains linked together. Free light chains, Kappa or Lambda light chains that have become unbound from the heavy chains, exist in very small amounts normally. Overproduction of immunoglobulins can cause an increase in the amount of free light chains circulating in the body. Measuring the FLC can be helpful as it is typically associated with a neoplastic increase of plasma cells in the body. The increased number of plasma cells causes an increased production in immunoglobulins and consequently an increase in FLC. Examples of diseases with increase of plasma cells are monoclonal gammopathy of undetermined significance, Multiple Myeloma, primary amyloidosis, some plasmacytomas, and can also be associated with autoimmune disease such as systemic lupus erythematosus. The Kappa/Lambda ratio is also calculated from the results of measuring the Kappa and Lambda levels in the body. This ratio can be used to assess kidney function. If both Kappa and Lambda levels are high, but the ratio is normal, it indicates that the kidneys are not eliminating the FLC as they do in normal patients. The ratio can also be used to monitor progression of disease from the time of diagnosis. As the ratio moves up and down, this correlates with the levels of Kappa and Lambda and changes with treatment, remission and possible recurrence of disease.

  • To diagnose and monitor patients with monoclonal gammopathies, such as Multiple Myeloma
  • As an aid in diagnosis of Waldenström macroglobulinemia
  • As an aid in diagnosis of monoclonal Light-Chain amyloidosis
  • Normal samples: Serum κ, λ, and κ:λ are all within the normal ranges. If accompanying serum electrophoretic tests are normal, it is most unlikely that the patient has no monoclonal gammopathy.
  • Abnormal κ:λ ratios: Supports the diagnosis of a monoclonal gammopathy and requires an appropriate bone marrow biopsy. Borderline elevated κ:λ ratios occur with renal impairment and may require appropriate renal function tests.
  • Low concentrations of κ, λ, or both: Indicates immunoglobulin immunodeficiency.
  • Elevated concentrations of both κ and λ with a normal κ:λ ratio: May be due to the following:
    • Renal impairment (common)
    • Overproduction of polyclonal FLCs from inflammatory conditions (common)
    • Biclonal gammopathies of different FLC types (rare)
  • Elevated concentrations of both κ and λ with an abnormal κ:λ ratio:Suggests a combination of monoclonal gammopathy and renal impairment.
Analyte mg/dL mg/L
Kappa 0.33–1.94 3.3–19.4
Lambda 0.571–2.62 5.71–26.3
K/L Ratio 0.26–1.65 2.6–11.65
Nephelometry.

Urine (Random or 24 hour) collected in a sterile urine container. 

Stability

  • Ambient: 12 hours
  • Refrigerated: 7 days
CBC with differential, Protein Electrophoresis with Reflex to Immunofixation, Bence Jones Protein, Qualitative Free Kappa & Lambda Light Chains in Urine, Beta-2 Microglobulin.
1-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Am J Hematol. 2011 Jun;86(6):475-8. doi: 10.1002/ajh.22025. [PMID: 21544856]
  • BMC Nephrol. 2008 Sep 22;9:11. [PMID: 18808676]
  • Br J Haematol. 2008 May;141(4):413-22. [PMID: 18318757]
  • J Immunol Methods. 1978; 19(4):341-9. [PMID: 416145]
  • Blood. 2001; 97(9):2900-2. [PMID: 11313287]
  • Clin Chem. 2002; 48(9):1437-44. [PMID: 12194920]
  • Acta Med Scand. 2009;(6):473-7. [PMID: 6266206]
  • http://www.aruplab.com/guides/ug/tests/0055167.jsp http://www.mayomedicallaboratories.com/test-catalog/Clinical
  • and
  • Interpretive/84190 Leukemia. 2009; 23:215-224
  • Multiple Myeloma NCCN Guidelines for Clinicians (NCCN.org) and patients (NCCN.com), 2010 Clin Chem. 2009; 55;1517-1522